Randomized, Placebo-Controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of ABBV-0805, an Anti-Alpha-Synuclein Monoclonal Antibody in Healthy Subjects
Objective: To evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of ABBV-0805 following administration of single ascending doses of ABBV-0805, administered as intravenous (IV) infusions…Towards an automated rating of the MDS-UPDRS motor scores.
Objective: This study aimed at developing an automated rating method for the MDS-UPDRS motor scores in Parkinson’s disease (PD) patients. This automated rating uses inertial…Remote Art Therapy is feasible and may benefit individuals with Parkinson’s disease
Objective: To evaluate the feasibility of remote art therapy (rAT) for patients with Parkinson’s disease (PD), and compare psychosocial outcomes to in-person AT (ipAT). Background:…Informing the design of disease modifying trials for Parkinson’s disease – A Delphi study
Objective: To assemble an international, multi-stakeholder Delphi panel to seek consensus on trial methodology for an adaptive trial platform investigating disease modifying therapies (DMTs) in…Early versus later levodopa and onset of motor fluctuations in PD: Observations from the Parkinson’s Outcomes Project
Objective: To characterize patients with early versus later levodopa exposure, defining “early” as within 2 years of Parkinson’s disease (PD) diagnosis, and to determine whether…THE EFFECT OF VITAMIN D IN PARKINSON’S DISEASE
Objective: The objective of this study is to investigate the role of vitamin D deficiency (VDD) as an etiopathological factor in Parkinson's disease (PD). Background:…Safinamide Improves Mood in Parkinson´s Disease. Results from the SAFINONMOTOR Study.
Objective: Our aim was to analyze the effectiveness of safinamide on mood in Parkinson´s disease (PD) patients from the SAFINONMOTOR (an open-label study of the…Effect of H. pylori Infection on L-DOPA Pharmacokinetics in Patients with Parkinson’s disease.
Objective: To evaluate whether Helicobactor pylori (H.pylori) infection affects the pharmacokinetics of L-DOPA in patients with Parkinson’s disease (PD). Background: H. pylori infects gastric mucosa…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.